特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

前立腺特異抗原:パイプライン製品の分析

Prostate Specific Antigen - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 369080
出版日 ページ情報 英文 78 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.59円で換算しております。
前立腺特異抗原:パイプライン製品の分析 Prostate Specific Antigen - Pipeline Review, H1 2020
出版日: 2020年02月28日 ページ情報: 英文 78 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

当レポートでは、前立腺特異抗原を標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

前立腺特異抗原 概要

治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療領域別
  • 開発中の製品:症状別

パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で開発中の製品

治療薬の評価

  • 単剤/併用治療薬の場合
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Advaxis, Inc.
  • Aeterna Zentaris Inc.
  • Bavarian Nordic A/S
  • Curevac AG
  • GenSpera, Inc.
  • Inovio Pharmaceuticals, Inc.
  • OncBioMune Pharmaceuticals Inc.

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

主なニュースおよびプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Advaxis Inc, H1 2020
  • Pipeline by Bavarian Nordic A/S, H1 2020
  • Pipeline by Etubics Corp, H1 2020
  • Pipeline by Hookipa Pharma Inc, H1 2020
  • Pipeline by Inovio Pharmaceuticals Inc, H1 2020
  • Pipeline by NantKwest Inc, H1 2020
  • Pipeline by Ohana Vaccine LLC, H1 2020
  • Pipeline by OncBioMune Pharmaceuticals Inc, H1 2020
  • Pipeline by OncoQuest Inc, H1 2020
  • Dormant Projects, H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
目次
Product Code: GMDHC2284TDB

Summary

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Prostate-specific antigen (PSA) is a glycoprotein enzyme encoded by the KLK3 gene. PSA is secreted by the epithelial cells of the prostate gland. It is hydrolyzes semenogelin-1 this leads to the liquefaction of the seminal coagulum.

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 2, 2 and 2 respectively. Similarly, the universities portfolio in Phase II stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Prostate Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and Hormone-Sensitive Prostate Cancer.

The latest report Prostate Specific Antigen - Pipeline Review, H1 2020, outlays comprehensive information on the Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)
  • The report reviews Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

Introduction

  • Global Markets Direct Report Coverage
  • Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Overview
  • Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Companies Involved in Therapeutics Development
  • Advaxis Inc
  • Bavarian Nordic A/S
  • Etubics Corp
  • Hookipa Pharma Inc
  • Inovio Pharmaceuticals Inc
  • NantKwest Inc
  • Ohana Vaccine LLC
  • OncBioMune Pharmaceuticals Inc
  • OncoQuest Inc
  • Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Drug Profiles
  • ADXS-PSA - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy to Target PSA for Prostate Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ETBX-071 + ETBX-061 + ETBX-051 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HB-301 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • INO-5150 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • INO-5151 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonl Antibody to Inhibit PSA for Prostate Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Pro-V vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ProscaVax - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rilimogene galvacirepvec - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target Brachyury Protein, KLK3 and MUC1 for Castration Resistant Prostate Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target Prostate Specific Antigen for Metastatic Hormone Refractory Prostate Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Dormant Products
  • Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Discontinued Products
  • Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Product Development Milestones
  • Featured News & Press Releases
  • Feb 13, 2020: Advaxis announces updated survival data in phase 1/2 ADXS-PSA trial at the ASCO Genitourinary Cancers Symposium
  • Jan 30, 2020: Data on Advaxis' clinical program ADXS-PSA to be presented at upcoming medical meetings
  • Oct 07, 2019: Advaxis announces updated prolonged survival data in phase 1/2 ADXS-PSA trial
  • May 14, 2019: Advaxis announces poster presentation on ADXS-PSA at the Frontiers in Cancer Immunotherapy Conference
  • May 07, 2019: Advaxis presents on its prostate cancer drug candidate ADXS-PSA at upcoming industry conferences
  • Apr 01, 2019: ADXS-PSA in combination with Keytruda prolonged survival in metastatic castration-resistant prostate cancer
  • Mar 19, 2019: Phase 2 trial of OncBioMune's immunotherapy cancer vaccine ProscaVax for prostate cancer patients in active surveillance now open for enrollment
  • Mar 11, 2019: Advaxis announces presentation of ADXS-PSA data at upcoming American Association for Cancer Research Annual Meeting
  • Jan 25, 2019: Data highlighting potential benefits of lm platform presented at 2019 Keystone Symposia Conference on cancer vaccines
  • Dec 07, 2018: Site visit planned for December 19, 2018 to initiate phase 2 Trial of ProscaVax for early-stage prostate cancer
  • Nov 08, 2018: OncBioMune phase 2 clinical trial to begin enrollment; company announces other development and corporate milestones
  • Nov 02, 2018: Advaxis provides update on its Prostate Cancer drug candidate ADXS-PSA
  • Oct 31, 2018: OncBioMune CEO Dr. Jonathan head speaking at 2018 global summit on genitourinary malignancies
  • Oct 22, 2018: Inovio Presents Progression Free Survival & PSA Doubling Time Improvements in Prostate Cancer Patients Treated with INO-5150
  • Oct 16, 2018: OncBioMune Signs Work Order for Phase 2 Clinical Trial of ProscaVax for Late Stage Prostate Cancer
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer